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A B S T R A C T
Background
This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.
Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal
blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Nasal
saline irrigation is commonly used to improve patient symptoms.
Objectives
To evaluate the effects of saline irrigation in patients with chronic rhinosinusitis.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015,
Issue 9); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of
the search was 30 October 2015.
Selection criteria
Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing saline delivered to the nose by any
means (douche, irrigation, drops, spray or nebuliser) with (a) placebo, (b) no treatment or (c) other pharmacological interventions.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related
quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included
general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation and
discomfort. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included two RCTs (116 adult participants). One compared large-volume (150 ml) hypertonic (2%) saline irrigation with usual
treatment over a six-month period; the other compared 5 ml nebulised saline twice a day with intranasal corticosteroids, treating
participants for three months and evaluating them on completion of treatment and three months later.
Large-volume, hypertonic nasal saline versus usual care
One trial included 76 adult participants (52 intervention, 24 control) with or without polyps.Disease-specific HRQL was reported
using the Rhinosinusitis Disability Index (RSDI; 0 to 100, 100 = best quality of life). At the end of three months of treatment, patients
in the saline group were better than those in the placebo group (mean difference (MD) 6.3 points, 95% confidence interval (CI) 0.89
to 11.71) and at six months there was a greater effect (MD 13.5 points, 95% CI 9.63 to 17.37). We assessed the evidence to be of low
quality for the three months follow-up and very low quality for the six months follow-up.
Patient-reported disease severity was evaluated using a “single-item sinus symptom severity assessment” but the range of scores is not
stated, making it impossible for us to determine the meaning of the data presented.
No adverse effects data were collected in the control group but 23% of participants in the saline group experienced side effects including
epistaxis.
General HRQL was measured using SF-12 (0 to 100, 100 = best quality of life). No difference was found after three months of
treatment (low quality evidence) but at six months there was a small difference favouring the saline group, which may not be of clinical
significance and has high uncertainty (MD 10.5 points, 95% CI 0.66 to 20.34) (very low quality evidence).
Low-volume, nebulised saline versus intranasal corticosteroids
One trial included 40 adult participants with polyps. Our primary outcome of disease-specific HRQL was not reported. At the end of
treatment (three months) the patients who had intranasal corticosteroids had less severe symptoms (MD -13.50, 95% CI -14.44 to -
12.56); this corresponds to a large effect size. We assessed the evidence to be of very low quality.
Authors’ conclusions
The two studies were very different in terms of included populations, interventions and comparisons and so it is therefore difficult
to draw conclusions for practice. The evidence suggests that there is no benefit of a low-volume (5 ml) nebulised saline spray over
intranasal steroids. There is some benefit of daily, large-volume (150 ml) saline irrigation with a hypertonic solution when compared
with placebo, but the quality of the evidence is low for three months and very low for six months of treatment.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence for the benefits and harms of nasal saline irrigation in patients with chronic rhinosinusitis.
Background
Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients with chronic rhinosinusitis experience at least two or more of the following symptoms
for at least 12 weeks: blocked nose, discharge from their nose or runny nose, pain or pressure in their face and/or a reduced sense of
smell (hyposmia). Some people will also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the nasal
passage and sinuses.
Nasal irrigation (also know as nasal douche, wash or lavage) is a procedure that rinses the nasal cavity with isotonic or hypertonic saline
(salt water) solutions. The patient instils saline into one nostril and allows it to drain out of the other nostril, bathing the nasal cavity.
Saline nasal irrigation can be performed with low positive pressure from a spray, pump or squirt bottle, with a nebuliser or with gravity-
based pressure using a vessel with a nasal spout, such as a ’neti pot’. This therapy is available over the counter and is used as a standalone
or add-on treatment by many patients with chronic rhinosinusitis.
Study characteristics
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We included two randomised controlled trials with a total of 116 adult participants in this review. One compared large-volume (150
ml) hypertonic saline irrigation with usual treatment over a six-month period. The other compared 5 ml of nebulised saline twice a
day with intranasal corticosteroids, treating participants for three months and evaluating them on completion of treatment and three
months later. Both of these studies had important limitations in their methodology and we considered them to have a high risk of bias.
Key results and quality of the evidence
Large-volume, hypertonic nasal saline versus usual care
In the small trial of 76 participants our primary outcome of ’disease-specific health-related quality of life’ was reported using a 0- to
100-point scale. At the end of three months of treatment, patients in the saline group were better than those in the placebo group and
at six months of treatment there was a greater effect. We assessed the evidence to be of low quality for the three months follow-up and
very low quality for the six months follow-up.
Patient-reported disease severity was also evaluated but the trialists did not state the range of scores used, which made it impossible for
us to determine the meaning of the data presented.
No adverse effects data were collected in the control group but 23% of participants in the saline group experienced side effects including
nosebleeds (epistaxis).
General health-related quality of life was also measured in this study. No difference was found after three months of treatment but at
six months there was a small difference (although the result is uncertain). We assessed the evidence to be of low quality.
Low-volume, nebulised saline versus intranasal corticosteroids
One small trial had 20 patients in each of the two arms being compared. Our primary outcome of disease-specific health-related quality
of life was not reported. At the end of treatment (three months) there was an improvement in symptoms.
Conclusions
The two studies were very different in terms of included populations, interventions and comparisons and so it is therefore difficult
to draw conclusions for practice. The evidence suggests that there was no benefit of a low-volume (5 ml) nebulised saline spray over
intranasal steroids, but there may be some benefit of daily, large-volume (150 ml) saline irrigation with a hypertonic solution compared
with placebo, although the quality of the evidence was low for three months and very low for six months of treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nasal saline (hypertonic) versus usual care for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Setting: most pat ients recruited f rom primary care
Intervention: nasal saline, hypertonic (2%), large-volume (150 ml), used every day
Comparison: usual treatment
Outcomes
of participants
(studies)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without nasal saline With nasal saline (hyper-
tonic, 2%, large-volume,
150 ml)
Difference
Disease-specif ic HRQL -
measured as change f rom
baseline using the RSDI
(range 0 to 100) at 3 months
follow-up
Higher score = better
of part icipants: 76
(1 RCT)
The mean change f rom
baseline was 7.7 points
The mean change f rom
baseline was 14 points
The mean disease-specif ic
HRQL score was 6.3 points
higher (0.89 higher to 11.
71 higher) than the usual
treatment group
⊕⊕©©
LOW 123
People who used nasal saline
irrigat ion had better quality of
lif e (moderate ef fect size)
Disease-specif ic HRQL -
measured as change f rom
baseline using the RSDI
(range 0 to 100) at 6 months
follow-up
Higher score = better
of part icipants: 76
(1 RCT)
The mean change f rom
baseline was 0.9 points
The mean change f rom
baseline was 14.4 points
The mean disease-specif ic
HRQL score was 13.5
higher (9.63 higher to 17.37
higher) than the usual treat-
ment group
⊕⊕©©
VERY LOW 124
People who used nasal saline
irrigat ion had better quality of
lif e (large ef fect size)
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Disease severity - measured
as change using a sin-
gle-item score (range not
known) at 3 months follow-
up
Lower score = better
of part icipants: 76
(1 RCT)
The mean change f rom
baseline was -0.3
The mean change f rom
baseline was -1.2
The mean change in dis-
ease severity score was 0.9
points lower (1.45 lower to
0.35 lower) than the usual
treatment group
⊕⊕©©
LOW 123
People who used nasal saline
irrigat ion seemed to report less
severe symptoms (moderate
ef fect size)
Disease severity measured
as change using a sin-
gle-item score (range not
known) at 6 months follow-
up
Lower score = better
of part icipants: 76
(1 RCT)
The mean change f rom
baseline was -0.005
The mean change f rom
baseline was -1.6
The mean change in dis-
ease severity score was 1.
59 points lower (2.15 lower
to 1.04 lower) than the usual
treatment group
⊕⊕©©
VERY LOW 124
People who used nasal saline
irrigat ion seemed to report less
severe symptoms (large ef fect
size)
Generic HRQL - measured
using the SF-12 (range 0 to
100) at 3 months follow-up
Higher score = better
of part icipants: 76
(1 RCT)
The mean score was 2.9
points
The mean score was 8.2
points
The mean generic HRQL
- measured using SF-12
(range 0 to 100) at 3 months
follow-up in the interven-
t ion group was 5.3 points
higher (4.38 lower to 14.98
higher) than the usual treat-
ment group
⊕⊕©©
LOW 123
It was unclear whether there
was a dif ference between
groups in generic HRQL
Generic HRQL - measured
using the SF-12 (range 0 to
100) at 6 months follow-up
Higher score = better
of part icipants: 76
(1 RCT)
The mean score was 2.2
points
The mean score was 12.7
points
The mean generic HRQL
- measured using SF-12
(range 0 to 100) at 6 months
follow-up was 10.5 points
higher (0.66 higher to 20.34
higher) than the usual treat-
ment group
⊕⊕©©
VERY LOW 124
It was unclear whether there
was a dif ference between
groups in generic HRQL
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Adverse events Outcome was collected only in the saline group. ‘‘Ten subjects (23%) experienced side ef fects; 8 ident if ied nasal irritat ion, nasal burning, tearing,
nosebleeds, headache, or nasal drainage as occurring but ’not signif icant ’. Two subjects (3%) ident if ied nasal burning, irritat ion, and headache
as ’signif icant ’.’’
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HRQL: health-related quality of lif e; RCT: randomised controlled trial; RSDI: Rhinosinusit is Disability Index
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Open-label study. Outcomes are subject ive and reported by pat ients.
2Sample sizes are small and the study was randomised in a 2:1 manner.
3Most of the pat ients were recruited f rom primary care. This has good applicability to most pat ients.
4Patients were shown their results f rom baseline at the six-month follow-up, before they f illed out the quest ionnaire.
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B A C K G R O U N D
Description of the condition
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses characterised by two or more symptoms, one of
whichmust be nasal blockage/obstruction/congestion or nasal dis-
charge (anterior/posterior nasal drip). The other possible symp-
toms include facial pain/pressure, reduction or loss of sense of
smell (in adults) or cough (in children). Symptomsmust have con-
tinued for at least 12 weeks. In addition people must have either
mucosal changes within the ostiomeatal complex and/or sinuses as
evidenced by a computerised tomography (CT) scan and/or endo-
scopic signs of at least one of the following: nasal polyps, mucop-
urulent discharge primarily from middle meatus or oedema/mu-
cosal obstruction primarily in the middle meatus (EPOS 2012).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms, including
nasal obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life, reportedly
greater in several domains of the SF-36 than angina or chronic res-
piratory disease (Gliklich 1995). Acute exacerbations, inadequate
symptom control and respiratory disease exacerbation are com-
mon. Complications are rare, but may include visual impairment
and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore the potential differ-
ences between them.
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically (by
mouth) and include steroids, antibiotics and saline.
Description of the intervention
Nasal irrigation (also know as nasal douche, wash or lavage) is a
procedure that rinses the nasal cavity with isotonic or hypertonic
saline (salt water) solutions. It is performed by instilling saline
into one nostril and allowing it to drain out of the other nostril,
bathing the nasal cavity. Saline nasal irrigation can be performed
with low positive pressure from a spray, pump or squirt bottle,
with a nebuliser or with gravity-based pressure using a vessel with
a nasal spout, such as a neti pot. This therapy is available over the
counter and is used as a standalone or adjunct treatment by many
patients with chronic rhinosinusitis.
How the intervention might work
The exact mechanism of action of saline nasal irrigation is un-
known. Saline nasal irrigationmay improve nasal mucosa function
through several physiological effects, including direct cleansing of
mucus (mucus is a potential medium for bacterial growth; saline
thins mucus and helps to clear it out); removal of antigens, biofilm
or inflammatory mediators (thereby resolving inflammation); and
improved mucociliary function (as suggested by increased ciliary
beat frequency; Brown 2004). Both the method of irrigation and
the tonicity (concentration) of the saline solution may have an
impact on its effectiveness.
Why it is important to do this review
Nasal saline irrigation has been adopted widely based on the
presumption that it is safe, cheap and widely available. A 2007
Cochrane review assessed this intervention (Harvey 2007). How-
ever, this previous review had broad inclusion criteria, including
patients with very broadly defined chronic rhinosinusitis. In this
new review, which replaces the original, we have adopted a stricter
definition of chronic rhinosinusitis and aim not only to evaluate
the overall effectiveness of nasal saline irrigation but also, where
possible, that of various methods of delivery and concentrations.
We have looked at the benefits and harms of nasal saline compared
with no treatment or ’placebo’ and other treatments for chronic
rhinosinusitis, and its effects as an adjunct treatment in patients
with chronic rhinosinusitis who are also using other treatments,
such as intranasal corticosteroids, oral corticosteroids, antibiotics
or combinations.
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This review is one of a suite of Cochrane reviews looking at com-
monmanagement options for patients with chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Head 2016a; Head 2016b; Head
2016c), and we use the same outcome measures across the reviews.
We have not included studies designed to evaluate interventions
in the immediate peri-surgical period, which are focused on as-
sessing the impact of the intervention on the surgical procedure
or on modifying the post-surgical results (preventing relapse).
O B J E C T I V E S
To evaluate the effects of saline irrigation in patients with chronic
rhinosinusitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only to
be included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of the intervention on surgical
outcome.
Types of participants
Patients with chronic rhinosinusitis, whether with or without
polyps.
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• aspirin-exacerbated respiratory disease;
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Types of interventions
Saline, as an active treatment, delivered to the nose by any means
(douche, irrigation, drops, spray or nebuliser, using an intermit-
tent, continuous or pulsed strategy).
The comparators were: no treatment or placebo or other stan-
dard treatments such as intranasal corticosteroids, short-course
oral steroids and/or antibiotics.
There are other additives, such as xylitol, antibacterials and sur-
factants, which can be added to nasal saline irrigation, and there
are also other formulations, such as lactated Ringer’s solution. We
have not included these in this review.
The main comparison pairs were:
• nasal saline versus no treatment/placebo;
• nasal saline plus intranasal corticosteroids versus placebo or
no treatment plus intranasal corticosteroids.
Other possible comparison pairs included:
• nasal saline versus intranasal corticosteroids;
• nasal saline type A versus other types/delivery methods/
volumes of nasal irrigation;
• hypertonic versus isotonic saline.
This review is part of a larger series of six reviews for the treatment
of chronic rhinosinusitis:
• Intranasal steroids versus placebo or no intervention for
chronic rhinosinusitis (Chong 2016a).
• Different types of intranasal steroids for chronic
rhinosinusitis (Chong 2016b). This review compares different
classes, doses and delivery methods of intranasal corticosteroids
for chronic rhinosinusitis.
• Short-course oral steroids alone for chronic rhinosinusitis
(Head 2016a). This review compares short-course oral steroids
alone with placebo or no intervention, or against other
pharmacological interventions such as antibiotics or nasal saline
irrigation.
• Short-course oral steroids as an adjunct therapy for chronic
rhinosinusitis (Head 2016b). This review compares oral steroids
where they have been used as add-on therapy to other treatments
for chronic rhinosinusitis (such as intranasal corticosteroids,
antibiotics or saline solution).
• Saline irrigation for chronic rhinosinusitis (this review).
This review compares nasal saline irrigation for chronic
rhinosinusitis with both placebo/no intervention and with
intranasal corticosteroids, short-course oral steroids or
antibiotics.
• Systemic and topical antibiotics for chronic rhinosinusitis
(Head 2016c). This review compares both topical and systemic
antibiotics with placebo/no treatment, two different antibiotics
with each other and antibiotics with intranasal corticosteroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
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Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, we reported patient-reported individual symptom
scores for the following symptoms: nasal obstruction/blockage/
congestion, nasal discharge (rhinorrhoea), facial pressure/pain,
loss of sense of smell (adults), cough (children).
• Significant adverse effect: epistaxis.
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other local adverse effects: local irritation.
• Other local adverse effects: discomfort.
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
We grouped outcome measures into these time periods: three to
less than six months, six to 12 months and more than 12 months.
For adverse events, we analysed data from the longest time periods.
The adverse events that we aimed to collect from studies including
one of the various comparators listed above were the same as those
adverse events identified in the methods section of the companion
reviews assessing the effects of those interventions as primary treat-
ments. For example, for studies in which all participants received
intranasal corticosteroids, the list of adverse events also included
those specifically for intranasal corticosteroids as found in Chong
2016a and Chong 2016b.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 30 October 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane Register of Studies ENT Trials Register
(searched 30 October 2015);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 9);
• Ovid MEDLINE (1946 to October week 4 2015);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 30 October 2015);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 30 October 2015);
• Ovid EMBASE (1974 to 30 October 2015);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies) (searched 30 October 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 30 October 2015);
• Google Scholar (searched 30 October 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials.
Data collection and analysis
Selection of studies
At least two review authors independently screened all titles and
abstracts of the studies obtained from the database searches to
identify potentially relevant studies. At least two review authors
evaluated the full text of each potentially relevant study to deter-
mine if it met the inclusion and exclusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and/methodological
input where necessary.
Data extraction and management
Two review authors independently extracted data from each study
using a standardised data collection form (see Appendix 2).When-
ever a study had more than one publication, we retrieved all pub-
lications to ensure complete extraction of data. Where there were
discrepancies in the data extracted by different review authors, we
checked these against the original reports and resolved differences
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by discussion and consensus, with the involvement of a third au-
thor or amethodologist where appropriate.We contacted the orig-
inal study authors for clarification or for missing data whenever
possible. If differences were found between publications of a study,
we contacted the original authors for clarification. We used data
from the main paper(s) if no further information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• presence or absence of nasal polyps;
• baseline nasal polyps score;
• whether the patient has had previous sinus surgery.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we planned
to convert into binary data.
We prespecified the time points of interest for the outcomes in this
review. While studies may report data at multiple time points, we
only extracted the longest available data within the time points of
interest. For example, for ’short’ follow-up periods, our time point
was defined as ’three to six months’ post-randomisation. If a study
had reported data at three, four and six months, we only extracted
and analysed the data for the six-month follow-up.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. We followed the guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011), and
we used theCochrane ’Risk of bias’ tool.With this tool we assessed
the risk of bias as ’low’, ’high’ or ’unclear’ for each of the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
We summarised the effects of dichotomous outcomes (e.g. propor-
tion of patients with symptom resolution) as risk ratios (RR) with
CIs. For the key outcomes that we presented in the ’Summary of
findings’ table, we also expressed the results as absolute numbers
based on the pooled results and compared to the assumed risk. We
also planned to calculate the number needed to treat to benefit
(NNTB) using the pooled results. The assumed baseline risk is
typically either (a) the median of the risks of the control groups
in the included studies, this being used to represent a ’medium
risk population’ or, alternatively, (b) the average risk of the control
groups in the included studies is used as the ’study population’
(Handbook 2011). If a large number of studies were available, and
where appropriate, we had also planned to present additional data
based on the assumed baseline risk in (c) a low-risk population
and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD) or as standardised
meandifference (SMD) if different scales had beenused tomeasure
the same outcome. We planned to provide a clinical interpretation
of the SMD values.
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We contacted study authors via email whenever the outcome of
interest was not reported, if the methods of the study suggested
that the outcome had been measured. We did the same if not all
data required for meta-analysis had been reported, unless themiss-
ing data were standard deviations. If standard deviation data were
not available, we approximated these using the standard estima-
tion methods from P values, standard errors or 95% CIs if these
were reported as detailed in the Cochrane Handbook for Systematic
Reviews of Interventions (Handbook 2011). If it was impossible to
estimate these, we contacted the study authors.
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Apart from imputations for missing standard deviations, we con-
ducted no other imputations. However, we had to carry out calcu-
lations relating to disease severity (reported as symptom scores) as
most of the data were not measured using validated instruments
nor reported in a way that was comparable across studies (see ’Im-
puting total symptom scores’ below).
We extracted and analysed all data using the available case analysis
method.
Imputing total symptom scores
Where a paper did not present information for the total dis-
ease severity in terms of patient-reported symptom scores but did
present data for the results of individual symptoms, we used these
to calculate a total symptom score. In addition, some studies used
instruments that were not validated for patients with chronic rhi-
nosinusitis and contained many additional symptoms not relevant
to chronic rhinosinusitis. Whenever study reports provided suffi-
cient information to cover the important domains related to the
EPOS criteria for diagnosing chronic rhinosinusitis (EPOS 2012),
we added up these individual scores. These EPOS 2012 criteria
for chronic rhinosinusitis require at least two symptoms. One of
the symptoms must be either nasal blockage or nasal discharge,
and the other symptoms can include facial pressure/pain, loss of
sense of smell (for adults) or cough (for children). Where a mean
change or final value for individual symptoms was provided we
summed these to calculate an overall summed mean for the total
score. We calculated standard deviations for the total mean score
as if the symptom data were an independent, random variable that
was normally distributed.We acknowledge that there is likely to be
a degree of correlation between the individual symptoms, however
we used this process because themagnitude of correlation between
the individual symptoms is not currently well understood (no ev-
idence found). If the correlation is high, the summation of vari-
ables as discrete variables is likely to give a conservative estimate
of the total variance of the summed final score. If the correlation
is low, this method of calculation will underestimate the standard
deviation of the total score. However, the average patient-reported
symptom scores have a correlation coefficient of about 0.5; if this
is also applicable to chronic rhinosinusitis symptoms, the method
used should have minimal impact (Balk 2012). As this method
of calculation does not take into account weighting of different
symptoms (no evidence found), we downgraded all the disease
severity outcomes for lack of use of validated scales whenever this
occurred.
However, the studies found in this review did not report data in
a way that required imputation to calculate total symptom scores
and we did not need to use this method.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We assessed statistical heterogeneity by visually inspecting the for-
est plots and by considering the Chi² test (with a significance level
set at P value < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We sought further information from the study
authors. If no further information could be found, we noted this
as being a ’high’ risk of bias. There was frequently insufficient in-
formation to judge the risk of bias; we noted this as an ’unclear’
risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We planned to assess funnel plots if sufficient trials (more than 10)
had been available for an outcome. If we observed asymmetry of
the funnel plot, we planned to conduct more formal investigation
using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we planned to analyse
treatment differences as a risk ratio (RR) calculated using theMan-
tel-Haenszel methods. We planned to analyse time-to-event data
using the generic inverse variance method.
For continuous outcomes, if all the data were from the same scale,
we planned to poolmean values obtained at follow-upwith change
outcomes and report this as a MD. However, if the SMD had to
be used as an effect measure, we would not have pooled change
and endpoint data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
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Subgroup analysis and investigation of heterogeneity
We planned to conduct some subgroup analyses regardless of
whether statistical heterogeneity was observed, as these are widely
suspected to be potential effect modifiers. For this review, this in-
cluded:
• phenotype of patients: whether patients have chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, a mixed group or the status of polyps is not known
or not reported. We planned to undertake this subgroup analysis
because although there appears to be a considerable overlap
between the two forms of chronic rhinosinusitis with regards to
inflammatory profile, clinical presentation and effect of
treatment (Cho 2012; DeMarcantonio 2011; Ebbens 2010;
EPOS 2007; Ragab 2004; Ragab 2010; van Drunen 2009), there
is some evidence that points to differences in the respective
inflammatory profiles (Kern 2008; Keswani 2012; Tan 2011;
Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even differences in treatment outcome (Ebbens 2011). Sinus
penetration of irrigation fluids differs in patients with and
without polyps, and according to whether previous sinus surgery
has been conducted (Brown 2004).
Weplanned topresent themain analyses of this review according to
the subgroups of phenotypes of chronic rhinosinusitis.Weplanned
to present all other subgroup analysis results in tables.
When studies had amixed group of patients, we planned to analyse
the study as one of the subgroups (rather than as a mixed group) if
more than 80% of patients belonged to one category. For example,
if 81% of patients had chronic rhinosinusitis without nasal polyps,
we would have analysed the study as that subgroup.
In addition to the subgroups above, we planned to conduct the
following subgroup analyses in the presence of statistical hetero-
geneity:
• patient age (children versus adults);
• dose (volume or frequency);
• tonicity;
• duration of treatment;
• method of delivery.
Sensitivity analysis
We planned to carry out sensitivity analyses to determine whether
the findings were robust to the decisions made in the course of
identifying, screening and analysing the trials. We planned to con-
duct sensitivity analysis for the following factors, whenever possi-
ble:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we defined these as studies that had a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed);
• how outcomes were measured: we planned to investigate
the impact of including data where the validity of the
measurement is unclear.
If any of these investigations had found a difference in the size of
the effect or heterogeneity, we would have mentioned this in the
Effects of interventions section.
GRADE and ’Summary of findings’ table
We
used the GRADE approach to rate the overall quality of evidence
using the GDT tool (http://www.guidelinedevelopment.org/) for
the main comparison pairs listed in the Types of interventions sec-
tion. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we applied this in
the interpretation of results. There are four possible ratings: ’high’,
’moderate’, ’low’ and ’very low’. A rating of ’high’ quality evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of ’very low’ quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ table presents only the seven top pri-
ority outcomes (disease-specific HRQL, disease severity score, ad-
verse effects and generic quality of life score). We did not include
the outcomes of endoscopic score and CT scan score in the ’Sum-
mary of findings’ table.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 1214 references after removal of
duplicates. We screened titles and abstracts and subsequently re-
moved 1175 references.We assessed 39 full texts for eligibility.We
excluded 28 studies (32 references), with reasons.We included two
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studies. We identified four references to ongoing studies. There
are no studies awaiting assessment.
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
Two studies met the criteria for inclusion (Cassandro 2015;
Rabago 2002). See Characteristics of included studies for full de-
tails.
Design and sample sizes
Both studies were non-blinded randomised controlled trials.
One study treated and followeduppatients for a total of sixmonths
(Rabago 2002), whereas the other treated patients for threemonths
and then followed them up for a further three months (Cassandro
2015).
The two studies were small, recruiting 76 (Rabago 2002) and
80 participants (Cassandro 2015). Only 40 participants in the
Cassandro study (20 in each intervention arm) received relevant
interventions for this review. Rabago 2002 randomised patients in
a 2:1 ratio: there were 52 participants in the saline group and 24
participants in the control group.
Setting
Rabago 2002 took place in theUSA and included participants who
were mostly (about 80%) from primary care settings. Cassandro
2015 was conducted in Italy, in a secondary care setting.
Participants
Both studies included adults (18 to 65 years old). Cassandro
2015 had almost equal numbers of male and female participants,
whereas the participants in Rabago 2002 were predominantly fe-
male: 75% in the control group and 71% in the intervention
group. There were few smokers in Rabago 2002 (4% and 1%
of the control and intervention participants), whereas half of the
population of Cassandro 2015 were smokers.
Rabago 2002 recruited patients by screening the billing databases
for the University of Wisconsin primary care and ENT practices
for billing codes of acute and chronic sinusitis (using the Inter-
national Classification of Diseases, (ICD), 9th revision codes of
ICD 461 and ICD 473 respectively). Adult patients with at least
two episodes of acute sinusitis or one episode of chronic sinusitis
per year for two consecutive years (n = 602) were sent a letter ex-
plaining the study and inviting participation. This definition of
chronic rhinosinusitis is different from that agreed in EPOS 2012.
Cassandro 2015 defined chronic rhinosinusitis as a duration of
12 weeks of at least two of the following nasal symptoms: in-
flammation of the nose and paranasal sinuses, nasal obstruction,
postnasal drip, sneezing, cough, olfactory disturbance, facial pain,
snoring and nasal dryness. Although the authors state that this was
“in accordance with current clinical guidelines”, it is unclear to
which clinical guidelines they are referring. Inflammation, sneez-
ing, cough, snoring and nasal dryness do not form part of the
EPOS definition of chronic rhinosinusitis.
Interventions
Nasal saline (hypertonic, 2%, large-volume, 150 ml) versus
no intervention
In Rabago 2002, participants in the intervention group were in-
structed to irrigate the nose daily for six months with the Sinu-
Cleanse nasal cup: 150 ml through each nostril of a solution con-
taining 2.0% saline buffered with baking soda. The solution of
one heaped teaspoon of canning salt, one-half teaspoon of baking
soda and one pint of tap water was freshly mixed by the patient
every one to two days.
Control participants continued with treatment of sinus disease in
their usual manner. All participants were telephoned at two weeks
to assess initial compliance with study protocols and thereafter if
assessment instruments were not returned promptly.
There is no description of what the allowed concurrent interven-
tions were. However, the study collected data for antibiotics and
“nasal spray” use every two weeks and noted that the use of antibi-
otics and nasal sprays (“percentage of 2 week blocks” when these
treatments were used) was about two times higher in the control
group.
Intranasal corticosteroids versus nasal saline (nebulised, 5
ml)
Cassandro 2015 comprised four groups, two of which are relevant
to this review:
• nebulised saline: aerosol therapy (NEBULA, Air Liquide
Medical Systems Italy) with 5 ml of saline twice daily;
• intranasal corticosteroid spray: mometasone furoate nasal
spray 200 µg twice daily.
Outcomes
Rabago 2002 assessed patients with questionnaires at baseline and
at 1.5, three and six months. At the six-month assessment partic-
ipants were shown their baseline answers for comparison, but not
at 1.5 and three months. Compliance with nasal irrigation was
recorded in a daily diary.
• Disease-specific health-related quality of life (HRQL) was
measured using the RSDI (Rhinosinusitis Disability Index), a
validated disease-specific instrument assessing quality of life in
emotional, functional and physical domains.
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• Quality of life was also measured using the general health
assessment Medical Outcomes Survey Short Form (SF-12).
• Overall sinus symptom severity was measured with a Single-
Item Symptom Severity Assessment (SIA) on a Likert scale
(range not specified) (there is no indication this was validated).
• The presence or absence of sinus symptoms (headache,
congestion, facial pressure, facial pain, nasal discharge),
antibiotic and nasal spray use, and overall satisfaction with use
was measured using an “exit questionnaire” at end of the study
(six months).
This study did not use endoscopy or CT scans, either at baseline
or as an outcome measure.
Cassandro 2015 assessed patients before therapy, at one month
and at three months following treatment initiation and at three
months following its cessation.
• Assessment of symptoms was recorded by the patient and
guardian using a validated 10 cm visual analogue scale (VAS).
However, it is unclear how these were eventually scored and
analysed.
• Nasal endoscopy, using a modified Lund-Mackay score, by
two otorhinolaryngologists.
• Axial and coronal computed tomography (CT) scans of the
nose and paranasal sinuses were scored using the Lund-Kennedy
score.
Source of funding and conflict of interest
Declarations of interest were not provided in either report.
Rabago 2002 reported that the study was supported by the Small
Grant Program from the Department of Family Medicine, Uni-
versity ofWisconsin, Madison. Cassandro 2015 did not report the
source of funding, but noted that they received editorial assistance,
which was “sponsored by IBSA”. IBSA is the manufacturer of neb-
ulised sodium hyaluronate, which was included in the treatment
arms not considered for this review.
Excluded studies
We excluded 28 studies (32 references) after reading the full-text
articles. Further details of the reasons for exclusion can be found
in the Characteristics of excluded studies tables.
Of these studies we excluded 20 due to the interventions or com-
parisonswithin the studies, which did notmeet the inclusion crite-
ria for this review (ACTRN12615000154505; Bachmann 2000;
Cho 2010; Cho 2015;Desrosiers 2001; Friedman 2006; Friedman
2012; Heatley 2000; Hunninghake 2012; NCT02097576;
NCT00924404; NCT01700725; Ottaviano 2011; Passali 2007;
Passali 2008; Passali 2008a; Pynnonen 2007; Salami 2000;
Taccariello 1999; Wendeler 1997). Interventions used in studies
that we excluded from the review included the use of irrigation
with xylitol, thermal waters and homeopathic remedies, as well as
the use of reflexology and antifungal agents.
We excluded five studies based on the included population. One
study only included people who underwent surgery within the
month prior to the trial (Jiang 2014). In four studies the popula-
tion included had perennial or seasonal allergic rhinitis (Cordray
2005;Garavello2003;Garavello2005;Rogkakou 2005). It should
be noted that all of these trials were included in the previous
Cochrane review (Harvey 2007), because the inclusion criteria for
patients comprised a wider population.
Three studies included comparisons that were valid and all other
aspects of the trial appeared to meet the inclusion criteria, with
the exception of the duration of treatment and follow-up (Culig
2010; Shoseyov 1998; Ural 2009). The minimum duration of fol-
low-up was set at three months. These studies followed up pa-
tients for 10 days (Ural 2009), 15 days (Culig 2010), and two
months (Shoseyov 1998). Ural 2009 was conducted in patients
with chronic rhinosinusitis, acute rhinosinusitis, allergic rhinitis
and in healthy volunteers to study the impact of saline irrigation
onmucociliary clearance. Culig 2010 compared hypertonic versus
isotonic seawater sprays, whereas Shoseyov 1998 treated children
with maxillary sinusitis with four weeks of hypertonic versus iso-
tonic saline and followed them up for another four weeks.
Ongoing studies
We iden-
tified four papers reporting ongoing studies (ISRCTN88204146;
NCT00335309; NCT02582099; TCTR20140323002). Three
of the trials are in adults with chronic rhinosinusitis. One trial aims
to compare saline irrigation, steam inhalation or a combination of
both daily for six months (ISRCTN88204146). NCT00335309
compares nasal saline irrigation with no irrigation as an adjunct to
antibiotic treatment. Treatment will be for 10 days but personal
communication from the authors confirmed that the follow-up
period will be for one year. TCTR20140323002 is a study that
aims to compare “warm saline irrigation” with “placebo”, although
it is unclear what the placebo is and no contact with the study
authors could be established.
The last study, conducted in children with chronic rhinosinusi-
tis and/or recurrent acute/subacute sinusitis, compares antibiotics
(gentamicin) with normal saline. It is due to be completed in De-
cember 2016, although the primary outcome measure appears to
be recurrence of sinusitis in a one-year follow-up period so it may
not assess an outcome of specific interest to this review.
Risk of bias in included studies
See Figure 2 for a ’Risk of bias’ graph (our judgements about
each risk of bias item presented as percentages across all included
studies) and Figure 3 for a ’Risk of bias’ summary (our judgements
about each risk of bias item for each included study).
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
17Saline irrigation for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Cassandro 2015 merely states that patients were “randomly” as-
signed to their treatment groups. The risk of bias is unclear.
We considered Rabago 2002 to be at low risk of bias for sequence
generation. “The randomization scheme was prepared by the In-
vestigational Drug Services of the University of Wisconsin Hos-
pital and Clinics. Subjects were stratified by smoking status and
then randomized by using an approximate 2:1 block design, with
10 subjects per block. Therefore 68% of subjects were assigned to
the experimental group and 32% to the control group.”
Allocation concealment
Cassandro 2015 provided no description of allocation conceal-
ment, therefore the risk of bias is unclear.
In Rabago 2002, one of the investigators “facilitated each infor-
mational meeting of 1 to 6 persons”. “Sealed envelopes contain-
ing the patient’s randomized group assignment were distributed
to subjects in the order they entered the room. The group assign-
ment was unknown to the investigator. Subjects broke the seal
and learned their assignment”. Although there seemed to be an
attempt to conceal allocation, we rated this as unclear risk of bias
because we were unsure whether the use of randomisation blocks
and a 2:1 design block could have affected concealment. More-
over, all the patients who were referred from the ENT clinic were
allocated into the saline group.
Blinding
Performance bias
Neither Cassandro 2015 nor Rabago 2002 blinded participants to
the type of treatments received. Therefore, we considered the risk
of bias to be high.
Detection bias
Most outcomes were subjective and in both studies patients were
not blinded to the treatment received (Cassandro 2015; Rabago
2002).
In Rabago 2002, patients were also allowed to see their baseline
results when they were asked to complete their questionnaires at
the final (six-month) follow-up, so that they could compare how
they felt at the beginning versus the end of the study. It also seemed
that only the participants in the active intervention group were
asked about side effects. Persons managing and analysing the data
also saw unblinded data but had no contact with participants.
Incomplete outcome data
Cassandro 2015 did not mention any loss to follow-up, or partic-
ipants not receiving interventions as intended. Therefore we con-
sidered this as an unclear risk of bias.
Rabago 2002 provided clear reporting on the people who dropped
out, compared the drop-outs against those who remained in the
study and attempted to telephone some patients who dropped
out to ascertain the reasons. The use of multiple regression to
impute the missing values and inclusion of all patients using the
intention-to-treat model was clearly specified. We considered the
risk of attrition bias to be unclear. Although drop-outs were not
high (12% in the saline group, 4% in the control group), the
proportion was larger in the treatment group. The baseline RSDI
is also about 10 points higher in the drop-out group - these are
the patients who were less unwell at baseline.
Selective reporting
The overall risk of selective reporting bias is unclear in both studies.
Rabago 2002 clearly reported all effectiveness outcomes and we
found no reason to suspect deviation from the planned analysis.
However, adverse events seemed to be collected only in the inter-
vention group and they reported the total number of people with
events.
In Cassandro 2015, effectiveness outcomes also seemed to be re-
ported as stated in the methods section, except for CT scan score
where it was stated that all groups showed improvement compared
to the saline group. However, they did not describe how the scores
were added up or analysed. There was no description in the meth-
ods of how adverse events were to be collected.
Other potential sources of bias
Use of validated outcome measures
Cassandro 2015 used 10 cm visual analogue scales (VAS). They
stated that “the 10-cm VAS we used consisted of a statistically
validated questionnaire that the patient filled out, answering the
question ’how troublesome are your symptoms of rhinosinusitis?’
is used. The answers range from 0 (not troublesome) to 10 (worst
thinkable troublesome)...”. However, they did not report fully on
how these scores were added up and analysed.
Rabago 2002 used validated scales for quality of life measures:
RSDI for disease-specific quality of life and SF-12 for generic qual-
ity of life. They made some minor amendment to some RSDI
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items to clarify that they were referring to the chronic rhinosinusi-
tis symptoms and this should not have a big impact on its validity.
There is less clarity on the validity and discriminant validity of the
Single Item Assessment “Likert scale” - the range of the scale was
not reported.
Baseline characteristics
In Rabago 2002, baseline risks appeared balanced but all the ENT
clinic participants ended up in the intervention group. Baseline
risk also appears balanced in Cassandro 2015 and is clearly re-
ported.
Effects of interventions
See: Summary of findings for the main comparison Nasal
saline versus usual care; Summary of findings 2 Intranasal
corticosteroids versus nasal saline
See Summary of findings for the main comparison; Summary of
findings 2.
Where the range of scales and the values for minimal impor-
tant differences (MID) were unclear, we used standardised mean
difference (SMD) to estimate the effect sizes. As suggested in
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), we used standard rules of thumb in the inter-
pretation of effect sizes (SMD or Cohen’s effect size of < 0.41 =
small, 0.40 to 0.70 = moderate, > 0.70 = large) (Cohen 1998).
Established scales such as the SF-12may have other rules of thumb
to estimate the minimal important difference (MID = 0.5 SMD)
and we use those to guide our interpretation whenever available
(Jaeschke 1989; Revicki 2008).
Comparison 1: Nasal saline (hypertonic, 2%, large-
volume, 150 ml) versus usual care
We found only one study for this comparison, with 76 participants
(Rabago 2002). Assessment of the effectiveness of the intervention
for the outcomes presented below should take into account the
higher “percentage of 2week blocks”whenpatients had used either
antibiotics or “nasal sprays” (or both) during the six-month study
period. In the control group antibiotics were used in an average
of 20% of the two-week blocks and nasal sprays were used in 8%.
These numbers were halved in the nasal saline group.
Primary outcomes
1. Health-related quality of life, using disease-specific
health-related quality of life scores
Rhinosinusitis Disability Index (RSDI) scores were used to mea-
sure this outcome (scale 0 to 100, higher score = better overall
quality of life). The change in mean RSDI from baseline among
treated participants was greater (better) with nasal saline than con-
trols at three and six months (Analysis 1.1).
At threemonths of follow-up, themeandifference (MD) in change
between baseline and three months between the groups was 6.30
(95% confidence interval (CI) 0.89 to 11.71; 76 participants).
This corresponds to a moderate effect size. The quality of the
evidence for this outcome was low, because the study was small
and unblinded.
At six months follow-up, the MD in change between baseline
scores and six months between the groups was 13.50 (95% CI
9.63 to 17.37; 76 participants). This corresponds to a large effect
size. The quality of the evidence was very low. In addition, this
was a small, unblinded study and participants were shown their
baseline ratings when filling out the questionnaires.
2. Disease severity, as measured by patient-reported symptom
score
This was measured using a “Likert scale” (range not described),
with higher scores indicating more severe symptoms. Patients were
asked “please evaluate the overall severity of your sinus symptoms
since you enrolled in the study” (Analysis 1.2).
At three months follow-up, the MD was -0.90 (95% CI -1.45 to
-0.35; 76 participants). This corresponds to a moderate to large
effect size.
At six months of follow-up, the MD was -1.59 (95% CI -2.15 to
-1.04; 76 participants). This corresponds to a large effect size.
The quality of the evidence is very low for the reasons stated earlier
and the validity of the scale is unclear.
3. Significant adverse effect: epistaxis
Adverse effects were not collected for the control group. In the
nasal saline group, “Ten subjects (23%) experienced side effects;
8 identified nasal irritation, nasal burning, tearing, nosebleeds,
headache, or nasal drainage as occurring but not significant.” Two
out of 46 participants (4%) identified nasal burning, irritation and
headache as “significant”.
Secondary outcomes
1. Health-related quality of life, using generic quality of life
scores
General health-related quality of life (HRQL) was measured using
the SF-12 (Analysis 1.3). The range of this score is 0 to 100, with
higher scores indicating better quality of life.
At three months follow-up (end of treatment), the MD in change
from baseline between the two groups was 5.30 (95% CI -4.38
to 14.98; 76 participants). The effect size (SMD 0.26, 95% CI -
0.23 to 0.74) is smaller than the commonly accepted threshold of
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0.5 SMD for a minimal important difference (MID) on the SF-
12.
At six months follow-up theMD in change from baseline between
the two groupswas 10.50 (95%CI 0.66 to 20.34; 76 participants).
The effect size (SMD 0.44, 95% CI -0.05 to 0.93) is less than the
commonly accepted MID threshold.
The quality of the evidence is low.
2. Other local adverse effects: local irritation
As reported above.
3. Other local adverse effects: discomfort
As reported above.
4. Endoscopic score (including nasal polyps score)
This was not assessed in the study.
5. Computerised tomography (CT) scan score
This was not assessed in the study.
Comparison 2: Intranasal corticosteroids versus nasal
saline (nebulised, 5 ml)
We found only one small study with 20 participants in each in-
tervention arm (Cassandro 2015).
1. Health-related quality of life, using disease-specific
health-related quality of life scores
This outcome was not reported in the study.
2. Disease severity, as measured by patient-reported symptom
score
This was measured using a 10 cm visual analogue “Likert scale”
(range not described), with higher scores indicating more severe
symptoms. Patients were asked “how troublesome are your symp-
toms of rhinosinusitis”. The range was from 0 (not troublesome)
to 10 (worst thinkable troublesome). They mentioned assessing
nasal obstruction, nasal discharge, postnasal drip, sneezing, cough,
olfactory disturbance, facial pain, snoring and nasal dryness. The
study reported an overall score, but it was unclear which symp-
toms were included in the analysis (i.e. whether this is a total score
for all symptoms measured) and therefore the scale range is not
known.
At three months follow-up (end of treatment), theMDwas -13.50
(95%CI -14.44 to -12.56; 40 participants), with less severe symp-
toms in the intranasal corticosteroids group. This corresponds to
a large effect size (SMD -8.71, 95% CI -10.81 to -6.60).
At six months follow-up (three months after end of treatment),
the MD was -7.71 (95% CI -8.72 to -6.70; 40 participants) with
less severe symptoms in the intranasal corticosteroids group. This
corresponds to a large effect size (SMD -4.63, 95% CI -5.87 to -
3.40).
The quality of the evidence is very low due to the lack of blinding
for a subjective outcome, the unclear validity and range of the
scale, and the very small sample size.
In addition to the symptom score, the study also assessed patients
every two weeks for individual symptoms. Patients on nasal saline
had fewer “2-week blocks” with nasal congestion, sinus headache
and frontal pain. The results are shown in Analysis 1.4.
3. Significant adverse effect: epistaxis
The risk ratio (RR) for epistaxis was 2.00 (95% CI 0.20 to 20.33;
40 participants), but the evidence is inconclusive due to the very
small sample size (very low quality evidence) (Analysis 2.2). The in-
tranasal corticosteroids group (2/20) had epistaxis compared with
the nasal saline group (1/20).
Secondary outcomes
1. Health-related quality of life, using generic quality of life
scores
This outcome was not reported in the study.
2. Other local adverse effects: local irritation
More patients in the intranasal corticosteroids group (1/20) re-
ported local irritation compared with the nasal saline group (0/
20); the RR was 3.00 (95% CI 0.13 to 69.52; 40 participants),
but the evidence is inconclusive due to the very small sample size
(very low quality evidence) (Analysis 2.2).
3. Other local adverse effects: discomfort
This was not reported as an adverse event.
4. Endoscopic score (including nasal polyps score)
The endoscopic scores were rated using a modified Lund-Mackay
scale. The range of this modified score was not reported. The
results are shown graphically in Analysis 2.3. The study indicated
that a lower score corresponds with an improvement.
At three months follow-up (end of treatment), the MD was -
14.57 (95% CI -15.15 to -13.99; 40 participants), favouring the
intranasal corticosteroids group.
At six months follow-up (threemonths after end of treatment), the
MDwas -7.37 (95%CI -8.22 to -6.52; 40 participants), favouring
the intranasal corticosteroids group.
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The quality of the evidence is low due to the small effect sizes and
lack of blinding. It is also unclear whether modification of the
scale affected its validity.
5. Computerised tomography (CT) scan score
This was assessed in the study but not fully reported. The study
only stated that CT scans in all groups showed improvement com-
pared to the saline group.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intranasal corticosteroids versus nasal saline for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Setting: secondary care
Intervention: intranasal cort icosteroids daily
Comparison: nasal saline, nebulised, small-volume (5 ml) used every day
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
With nasal saline (neb-
ulised, small- volume)
With intranasal corti-
costeroids
Difference
Disease-specif ic qual-
ity of lif e
- Outcome not measured or reported in the study
Disease severity - over-
all score (range not
known) at 3 months fol-
low-up (end of treat-
ment)
Higher score = worse
of part icipants: 40
(1 RCT)
- The mean score was 6.
6 points
The mean score was
20.1 points
The mean disease
severity - overall score
(range not known) - at 3
months follow-up (end
of treatment) in the in-
tervent ion group was
13.5 lower (14.44 lower
to 12.56 lower)
⊕©©©
VERY LOW 12
Patients
on intranasal cort icos-
teroids seemed to have
less severe symptoms
by the end of treatment
(large ef fect size)
Disease severity - over-
all score (range not
known) at 6 months fol-
low-up (3 months af ter
end of treatment)
Higher score = worse
of part icipants: 40
(1 RCT)
- The mean score was
13.19 points
The mean score was
20.9 points
The mean disease
severity - overall score
(range not known) - at
6 months follow-up (3
months af ter end of
treatment) in the inter-
vent ion group was 7.71
lower (8.72 lower to 6.
7 lower)
⊕©©©
VERY LOW 12
Patients
on intranasal cort icos-
teroids seemed to con-
t inue having less severe
symptoms 3 months
af ter treatment was
stopped (large ef fect
size)
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Adverse events - epis-
taxis
of part icipants: 40
(1 RCT)
RR 2.00
(0.20 to 20.33)
Study populat ion ⊕©©©
VERY LOW 13
More peo-
ple on intranasal cort i-
costeroids could have
epistaxis than those on
nebulised saline
50 per 1000 100 per 1000 50 more per 1000 with
INCS (80 fewer to 1933
more)
Adverse events - local
irritat ion
of part icipants: 40
(1 RCT)
RR 3.00
(0.13 to 69.52)
Study populat ion ⊕©©©
VERY LOW 13
More pat ients
on intranasal cort icos-
teroids could have lo-
cal irritat ion compared
to those on nebulised
saline
No events with nasal
saline reported
50 per 1000 Not est imable
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; INCS: intranasal cort icosteroids; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Open-label study. Outcomes assessed were subject ive. Method of sequence generat ion and allocat ion concealment unclear.
2Very small study. Could be suscept ible to small study ef fects (overest imation of ef fect sizes).
3Number of events and part icipants too small to est imate this precisely.
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D I S C U S S I O N
Summary of main results
We found only two very small, open-label studies with important
limitations (Cassandro 2015; Rabago 2002).
One of the studies investigated adding daily, large-volume (150
ml) hypertonic (2%) nasal saline irrigation to usual care (Rabago
2002). This study used validated quality of life outcomes and
found moderate to large effects in improvement of disease-spe-
cific (Rhinosinusitis Disability Index - RSDI) and generic (SF-12)
quality of life measures after three and six months of treatment,
respectively. This improvement was observed despite higher usage
of antibiotics and “nasal sprays” in the control group.
The other study compared intranasal corticosteroids versus nasal
saline nebulisation administered twice a day (Cassandro 2015).
This was not as effective as intranasal corticosteroids for the out-
comes of disease severity and endoscopy score that were measured.
Overall completeness and applicability of
evidence
We found little evidence on whether nasal saline is effective. The
two studies included were very different and had different control
groups; this makes comparison difficult. One study used high-
volume nasal saline irrigation (150 ml daily) with a hypertonic
saline solution in patients from primary care and might have in-
cluded both chronic and acute rhinosinusitis patients (Rabago
2002), whereas the other study compared low-volume nasal saline
(5 ml nebulised spray) with intranasal corticosteroids in people
with chronic rhinosinusitis in secondary care (Cassandro 2015).
There are three aspects of nasal saline irrigation that are important
to consider and for which we did not identify evidence during
this review: the volume of the irrigation, the method of delivery
and the tonicity of the solution used. With regards to volume
it is unclear whether there is a minimum volume that could be
considered to be irrigation. We found no studies that investigated
whether high-volume irrigation (such as the 150 ml daily used in
Rabago 2002) improves patient symptoms better than low-volume
irrigation. The volume administered will also be directly linked
to the method of delivery of irrigation to the nose and this is an
aspect that has not been studied. There are many widely available
commercial products that have different delivery methods, from
a nebulised spray that provides a ’mist’ of saline solution likely to
have the effect of moistening the inside of the nostrils, to products
where a sachet is mixed with water and then put into a bottle that
has been designed to aid in the delivery of saline to the sinuses.
We found no evidence to compare these. Lastly the tonicity of the
solution: isotonic saline is reported to improve mucociliary clear-
ance, most likely through mechanical cleaning, while it has been
proposed that hypertonic saline solutions may have an effect by
decreasing oedema and increasing mucociliary clearance through
stimulation of ciliary beat frequency, thinning of mucus and sup-
pression of inflammation (Ural 2009). There were no included
studies that directly compared hypertonic and isotonic nasal saline
solutions. Rabago 2002 used a hypertonic solution and there is
no information regarding the tonicity of the nasal spray used in
Cassandro 2015.
The advantage of nasal saline irrigation solutions is that they are
very accessible for patients, who may feel empowered by using
them (Rabago 2006). Solutions can be made and administered
at home and there are resources to help guide technique (such as
http://www.fammed.wisc.edu/nasal-irrigation/). The adverse ef-
fects of using nasal saline irrigation were not well reported in the
included trials, but based on these studies they are not likely to be
severe. Patients in a qualitative study have reported an initial fear
of having solution in the nasal cavity and an unpleasant sensation
during the irrigation process, however these were often overcome
with education and coached practice on nasal irrigation techniques
(Rabago 2006).
Quality of the evidence
We downgraded the quality of the evidence for effectiveness be-
cause it is drawn from only one very small study for each com-
parison. These studies had important methodological limitations,
which put them at high risk of bias. Although one of the studies
used validated scales for quality of life, it was uncertainwhether the
larger effects observed at six months (compared to three months)
were biased by the fact that patients were shown their scores at
baseline (Rabago 2002). Cassandro 2015 used a 0 to 10 mm vi-
sual analogue scale to score individual symptom severity, but they
did not provide any descriptions of how these were added up or
scored, and there was no information on the range of the scale.
Adverse events were collected only from the treatment arm in
Rabago 2002,making a comparisonwith the control group impos-
sible. As sample size of only 20 patients in each arm in Cassandro
2015 means that it is unlikely to provide any precise data to esti-
mate the risks of adverse events.
Potential biases in the review process
We imputed the standard deviations using standard methods,
based on the standard errors reported in Rabago 2002. This accu-
racy of this estimation could be affected by the small sample sizes.
Rabago 2002 was a study that was primarily conducted in pa-
tients seen in primary care. This study did not use the EPOS diag-
nostic criteria (EPOS 2012), but included patients who had two
consecutive years where they had at least one episode of chronic
rhinosinusitis and two episode of acute rhinosinusitis per year.
The symptom outcome of the study suggested that patients in
the control group had about 80% of the two-week blocks with
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most chronic rhinosinusitis symptoms.We decided to include this
study because we thought that this was representative of the popu-
lation presenting to primary care, although it should be noted that
they are a heterogenous group that includes acute rhinosinusitis
and may not represent chronic rhinosinusitis patients according
to clear definitions such as EPOS 2007 and EPOS 2012.
Agreements and disagreements with other
studies or reviews
This review only includes patients with chronic rhinosinusitis and
includes fewer studies than many other similar reviews on saline
(which have included studies of other groups of patients, such as
allergic rhinitis patients, and have often included non-randomised
trials). We conducted the review as part of a series of reviews look-
ing at the effectiveness of non-surgical interventions for chronic
rhinosinusitis (Chong 2016a; Chong 2016b; Head 2016a; Head
2016b; Head 2016c). In the four reviews on intranasal corticos-
teroids and oral corticosteroids, only two small studies specifically
did not allow the use of nasal saline irrigation (Kirtsreesakul 2012;
Vlckova 2009). It is unclear whether nasal saline was used widely
in other studies.
The previous Cochrane review on this topic included patients suf-
fering from rhinitis with seasonal exacerbations, perennial rhini-
tis, recurrent acute sinusitis in patients with ongoing symptoms
between exacerbations and chronic rhinosinusitis (Harvey 2007).
This review included eight studies and was only able to draw sim-
ilar conclusions to this review: “The beneficial effect of saline ap-
pears to outweigh the drawbacks for the majority of patients. Top-
ical saline could be included as a treatment adjunct for managing
the symptoms of chronic rhinosinusitis and conditions produc-
ing chronic sinonasal symptoms. There is no evidence that saline
is more effective than active agents. There is evidence that hy-
pertonic solutions improve mucociliary clearance (Talbot 1997;
Bachmann 2000). The effect on symptoms is less evident. There
may be some added clinical benefit but it is balanced against pa-
tient tolerance. No information can be provided regarding the de-
livery type, dosage frequency or volume.”
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review includes two studies, which are very different in terms
of their included populations, interventions and comparisons. It is
therefore difficult to draw conclusions for practice. The evidence
suggests there is no benefit of a low-volume (5 ml) nebulised saline
spray over intranasal steroids, but there is some benefit of daily,
large-volume (150 ml) saline irrigation with a hypertonic solution
compared with placebo, although the quality of the evidence was
low. No information can be provided on the tonicity, volume, de-
livery method, frequency or duration of use. Nasal saline irriga-
tions are easy for patients to administer and are unlikely to cause
severe adverse events. Patients may feel empowered through the
use of topical saline irrigation, although this must be balanced
against patient tolerance.
Implications for research
As of October 2015, we found only two very small, open-label
studies of nasal saline irrigation in people with chronic rhinosi-
nusitis. There is low-quality evidence (we are uncertain about the
estimates) to suggest that, for people with chronic rhinosinusitis, a
large-volume (150 ml) nasal saline irrigation intervention is effec-
tive in improving patients’ quality of life and symptoms compared
to usual care. This improvement was observed despite the higher
usage of antibiotics and “nasal sprays” in the control group. There
is very low-quality evidence to suggest that nasal saline nebulisa-
tion is not as effective as intranasal corticosteroids. These studies
had important methodological limitations, which puts them at
high risk of bias. The quality of the evidence for adverse effects
is very low due to inadequate reporting methods and small study
sizes.
We considered the potential for future research into the use of
nasal saline and feel that this area of research might not be priori-
tised above research for other standard interventions as identified
by the other reviews in this suite (Chong 2016a; Chong 2016b;
Head 2016a; Head 2016b; Head 2016c). If research is carried out,
open questions remain about the use of nasal saline irrigation in
patients with chronic rhinosinusitis, including the optimal vol-
ume of irrigation, delivery methods and tonicity of the solutions
used. In addition, the use of nasal saline solution as an adjunct
to other standard treatments also could be considered. Any trial
undertaken, however, should be designed as a randomised con-
trolled trial, including patients with chronic rhinosinusitis diag-
nosed using the EPOS 2012 criteria and include both patients
with and without nasal polyps (stratified randomisation by sub-
group). Future trials of saline irrigation for chronic rhinosinusitis
should focus on clinically relevant treatment comparisons; their
design should allow for comparison of different compositions of
saline solutions, tonicity, volume or delivery methods. The inter-
vention and follow-up should be carried out for at least three or six
months, since saline is used as a long-term treatment for a chronic
condition.
This review is one of a suite of reviews of medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
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• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes.
• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for chronic rhinosinusitis, agreed by researchers,
clinicians and patients, will facilitate this process.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cassandro 2015
Methods 4-arm, non-blinded, single-centre, parallel-group RCT, with 3 months of treatment and
a total of 6 months follow-up
Participants Location: Italy, single site, between September 2011 and April 2012
Setting of recruitment and treatment: Department of Otorhinolaryngology of the
University Hospital ’San Giovanni di Dio e Ruggi d’Aragona’ in Salerno
Sample size:
• Number randomised: 20 in intervention group, 20 in comparison group
• Number completed: no information
Participant (baseline) characteristics:
• Age (mean ± SD): NS 38.6 ± 13.06, INCS: 38.4 ± 12.70
• Gender (M/F): INCS: 10/10, NS:11/9
• Main diagnosis: chronic rhinosinusitis with nasal polyps
• Polyps status: 100%, modified Lund-Mackay score INCS about 23.1 (SD 1.3) in
both groups
• Previous sinus surgery status: no information
• Previous courses of steroids: no information
• Other important effect modifiers, if applicable (e.g. aspirin sensitivity,
comorbidities of asthma):
◦ Skin prick tests, % positive: INCS: 45, NS: 40
◦ Smoking (%): INCS: 40, NS: 55
◦ Time by the initial diagnosis (years) (mean ± SD): INCS: 4.45 ± 2.46, NS:
5.7 ± 5.19
Inclusion criteria:
• ≥ aged c18 years and had CRSwNP
• CRS defined as a duration of 12 weeks with the presence of at least 2 of the
following nasal symptoms: inflammation of the nose and paranasal sinuses, nasal
obstruction, postnasal drip, sneezing, cough, olfactory disturbance, facial pain, snoring,
nasal dryness. Endoscopy and CT used in confirming diagnosis.
• Not received any investigational drug therapy for 4 months before study started
Exclusion criteria: pregnant women
Interventions Intranasal corticosteroid (n = 20): mometasone furoate nasal spray (MFNS) 200 µg
twice a day
Nasal saline (n = 20): nebulised saline administered as aerosol therapy (NEBULA®,
Air Liquide Medical Systems Italy) with 5 ml of saline twice a day
Use of additional interventions (common to both treatment arms): nasal deconges-
tants and local anaesthesia were not used
Outcomes Outcomes of interest in the review:
Primary outcomes:
1.Disease severity symptom score using a validated 10 cmVAS for nasal obstruction, nasal
discharge, postnasal drip, sneezing, cough, olfactory disturbance, facial pain, snoring and
nasal dryness was recorded by the patient and guardian
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Cassandro 2015 (Continued)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Endoscopy, reported as “mean endoscopic score” - scored by 2 otorhinolaryngologists
using modified postoperative criteria for endoscopic appearance originally described by
Lund et al
4. CT scan - not fully reported
5. Adverse events: local irritation
Other outcomes reported by the study:
• Active anterior rhinomanometry
• Saccharine clearance test
Funding sources “Editorial assistance was provided by Raelene Simpson on behalf of in Science Com-
munications, Springer Healthcare. This assistance was sponsored by IBSA”. IBSA is the
manufacturer of nebulised sodium hyaluronate, included in treatment arms not consid-
ered for this review
Declarations of interest No information provided
Notes There are 2 other intervention groups in this trial:
• Nebulised sodium hyaluronate (aerosol therapy with 3 ml sodium hyaluronate 9
mg and 2 ml saline twice a day)
• INCS plus nebulised sodium hyaluronate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned”
Comment: no further description
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned”
Comment: no further description
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “…drug was administered on an
open-label basis”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “…drug was administered on an
open-label basis.”
Comment: subjective outcomes in a non-
blinded study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there was no mention of drop-
outs or exclusions
Selective reporting (reporting bias) Unclear risk Comment: outcomes seem to be reported
as stated in the methods section, except for
CT scan score where it was stated that all
groups showed improvement compared to
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Cassandro 2015 (Continued)
the saline group. There was no description
in the methods about how adverse events
were to be collected
Other bias Unclear risk Quote: “The 10-cm VAS we used con-
sisted of a statistically validated question-
naire that the patient filled out, answer-
ing the question ’how troublesome are your
symptoms of rhinosinusitis?’ is used. The
answers range from 0 (not troublesome) to
10 (worst thinkable troublesome)”
Comment: they did not fully report how
scores were added up and analysed
Rabago 2002
Methods 2-arm, unblinded, single-centre, parallel-group RCT, with a 6-month duration of treat-
ment and simultaneous follow-up
Participants Location: Wisconsin, USA, single site
Setting of recruitment and treatment: University of Wisconsin primary care and ear,
nose and throat (ENT) practices. About 80% of participants were from primary care,
the others were from an ENT clinic
Sample size:
• Number randomised: 52 in intervention, 24 in comparison
• Number completed: 46 in intervention, 23 in comparison
Participant (baseline) characteristics:
• Age: intervention: 42.4 ± 1.4, control: 41.4 ± 2.4
• Gender: female: intervention: 37 (71%), control: 18 (75%)
• Main diagnosis: 1 episode of chronic sinusitis for 2 consecutive years OR 2
episodes of acute sinusitis
◦ Acute sinusitis: intervention: 34 (65%), control: 20 (83%)
◦ Chronic sinusitis: intervention: 11 (21%), control: 2 (8%)
◦ Both (acute and chronic sinusitis): intervention: 7 (13%), control: 2 (8%)
• Polyps status: intervention: 9 (17%), control: 3 (13%)
• Previous sinus surgery status: intervention: 19 (37%), control: 7 (29%)
• Previous courses of steroids: not described
• Other important effect modifiers, if applicable (e.g. aspirin sensitivity,
comorbidities of asthma):
◦ Asthma: intervention: 14 (27%), control: 4 (17%)
Inclusion criteria: patients 18 to 65 years old with 2 episodes of acute sinusitis or 1
episode of chronic sinusitis per year for 2 consecutive years were contacted. Of these,
patients indicating “moderate to severe” impact of sinus symptoms on their quality of
life on a Likert scale of 1 to 7 were invited to participate.
Exclusion criteria: pregnancy and significant comorbidity precluding travel to ameeting
or use of saline irrigation
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Rabago 2002 (Continued)
Interventions Intervention (n = 52): 2.0% saline buffered with baking soda (1 heaping teaspoon of
canning salt, one-half teaspoon of baking soda and 1 pint of tap water), 150 ml through
each nostril daily for 6 months administered with the SinuCleanse nasal cup
Solution was mixed fresh every 1 to 2 days. Intervention duration was 6 months
Participants saw a brief demonstration film, witnessed nasal irrigation by the facilitator
and demonstrated proficiency with the nasal irrigation technique before departure
Comparator group (n = 24): continued treatment of sinus disease in their usual manner
Use of additional interventions (common to both treatment arms):
• All participants attended an “informational meeting” and heard a brief
presentation about sinus disease and its treatment. Nasal irrigation theory and
technique were explained.
• No further information on what other concurrent treatments were allowed.
However, the study reported the percentage of 2-week blocks with the use of the
following treatments:
◦ antibiotics: saline 10 ± 0.02, control: 19 ± 0.04 (statistically significant)
◦ nasal spray: saline: 4 ± 0.01, control: 8 ± 0.02 (not statistically significant
difference)
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, disease-specific using RSDI at 1.5, 3 and 6 months
(emotional and functional domains), range of 0 to 100
2. Disease severity symptom score: single-item symptom severity assessment (SIA):
“Please evaluate the overall severity of your sinus symptoms since you enrolled in the
study”. Likert scale
3. Significant adverse effect: epistaxis
Secondary outcomes:
4. Health-related quality of life, generic, using SF-12, range of 0 to 100
5. Adverse events: local irritation
Other outcomes reported by the study:
• Sinus symptoms: sinus headache, frontal pain, frontal pressure, nasal congestion,
nasal discharge
• Self reported compliance levels
Funding sources SmallGrant Program from theDepartment of FamilyMedicine,University ofWisconsin,
Madison
Declarations of interest No information provided
Notes Experimental participants reported using nasal irrigation on 87% of days during the
study; 31 participants reported using nasal irrigation on 91% or more days, 13 partic-
ipants on 76% to 90% of days, and 5 participants on 51% to 75% of days. Only 3
participants used nasal irrigation on 50% of days or less
Risk of bias
Bias Authors’ judgement Support for judgement
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Rabago 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “The randomization scheme was
prepared by the Investigational Drug Ser-
vices of theUniversity ofWisconsin Hospi-
tal and Clinics. Subjects were stratified by
smoking status and then randomized by us-
ing an approximate 2:1 block design, with
10 subjects per block”
Comment: randomisation schedule should
have been appropriately generated
Allocation concealment (selection bias) Unclear risk Quote: “One of us (D.R., R.M., or A.Z.
) facilitated each informational meeting of
1 to 6 persons. Sealed envelopes contain-
ing the patient’s randomized group assign-
ment were distributed to subjects in the or-
der they entered the room. The group as-
signment was unknown to the investigator.
Subjects broke the seal and learned their as-
signment”
Comment: envelopes given by order of ar-
rival at the meeting. Unclear whether the
usage of randomisation blocks could have
affected concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Subjects broke the seal and learned
their assignment. Thereafter, investigators
were not blind to subjects’ group assign-
ment.”
Comment: neither participants nor asses-
sors were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Persons managing and analysing
data also saw unblinded data but had no
contact with subjects”
“… at the 6-month assessment, subjects
were shown their baseline answers for com-
parison because they had told us they
needed to recall answers to past questions.
They believed they knew whether they felt
better or worse and wanted their later an-
swers to reflect this change”
Comment: there was no blinding at all.
Most of outcomes are subjective responses
from patients; showing patients their base-
line response could put this at a higher risk
of bias
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Rabago 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “As dictated by the intention-to-
treat model, the few missing values were
imputed with multiple regression”
“Dropouts tended to have slightly better
baseline RSDI scores than nondropouts,
66.8 vs 58.1 points, but this difference was
not significant (P = .15).”
Comment: drop-outs not high and clearly
documented (12% in saline, 4% in con-
trol), but the proportion is higher in the
intervention group. The baseline RSDI is
also about 10 points higher in the drop-out
group - these are the patients who were less
unwell at baseline
Selective reporting (reporting bias) Unclear risk All key outcomes fully reported. No reason
to suspect deviation from planned analysis.
However, adverse events seemed to be col-
lected only in the intervention group and
were reported as a total number of people
with events
Other bias Unclear risk Quote: “By chance all subjects from ENT
clinics (n = 6) and a disproportionate per-
centage of subjects with chronic sinusi-
tis were randomized to the experimental
group. Neither variable was statistically sig-
nificant.”
Comment: baseline risks appear balanced
but all the ENT clinic participants ended
up in the intervention group
Validated scales, RSDI and SF-12 were
used for quality of life. However, the dis-
criminant validity of SF-12 in CRS is still
not proven. There were minor modifica-
tions in the RSDI, which should not affect
its validity. There is less clarity on the valid-
ity and discriminant validity of the Single
Item Assessment “Likert scale”
CRS: chronic rhinosinusitis
CRSwNP: chronic rhinosinusitis with nasal polyps
CT: computerised tomography
F: female
INCS: intranasal corticosteroids
M: male
MFNS: mometasone furoate nasal spray
NS: nasal saline
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RCT: randomised controlled trial
RSDI: Rhinosinusitis Disability Index
SD: standard deviation
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12615000154505 INTERVENTION: xylitol versus saline; xylitol was not considered to be a standard treatment for CRS
Bachmann 2000 INTERVENTION: Ems salt solution (1.1%) versus sodium hydrochloride solution (0.9%)
Cho 2010 POPULATION: acute, subacute and chronic sinusitis
INTERVENTION: nasal irrigation using benzalkonium chloride, which has other chemical properties
(surfactant and antibacterial) - not a saline irrigation solution
Cho 2015 INTERVENTION: low concentration hypochlorous acid versus saline irrigation; hypochlorous irri-
gation is not considered to be a standard treatment for CRS
Cordray 2005 POPULATION: seasonal allergic rhinitis
Culig 2010 DURATION: treatment and follow-up only 15 days
Desrosiers 2001 INTERVENTION: antifungal irrigation versus saline irrigation
Friedman 2006 INTERVENTION: hypertonic dead sea salt irrigation versus hypertonic saline irrigation; not an in-
cluded comparison
Friedman 2012 INTERVENTION: hypertonic dead sea salt irrigation versus hypertonic saline irrigation; not an in-
cluded comparison
Garavello 2003 POPULATION: seasonal allergic rhinitis
Garavello 2005 POPULATION: seasonal allergic rhinoconjunctivitis
Heatley 2000 INTERVENTION: hypertonic saline irrigation with a bulb syringe versus hypertonic nasal irrigation
with a nasal irrigation pot versus reflexology on “established sinus contact points”
DURATION: follow-up only 2 weeks
Hunninghake 2012 INTERVENTION: homeopathic agent containing wild indigo versus nasal saline
Jiang 2014 POPULATION: all patients had surgery 1 month prior to starting trial
NCT00924404 INTERVENTION: xylitol versus saline solution
NCT01700725 INTERVENTION: xylitol versus saline solution
38Saline irrigation for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
NCT02097576 INTERVENTION: salinemixed withManuka honey versus saline only (note: the study was withdrawn
prior to enrolment)
Ottaviano 2011 INTERVENTION: sulphurous, salty, bromic, iodic (SSBI) thermal water versus isotonic sodium chlo-
ride solution (ISCS); SSBI not considered to be a standard CRS treatment
Passali 2007 INTERVENTION: intranasal glucan spray versus intranasal saline spray; glucan spray is not considered
to be a standard treatment
Passali 2008 INTERVENTION: treatment with thermal waters, which are not considered to be a standard CRS
treatment
Passali 2008a INTERVENTION: treatment with thermal waters, which are not considered to be a standard CRS
treatment
Pynnonen 2007 INTERVENTION: isotonic dead sea salt nasal spray (low-volume) versus isotonic saline rinse irrigation
(large-volume)
DURATION: follow-up only 8 weeks
Rogkakou 2005 POPULATION: persistent allergic rhinitis
Salami 2000 INTERVENTION: thermal waters versus sodium chloride 0.9%. Treatment with thermal waters,
which are not considered to be a standard CRS treatment
Shoseyov 1998 DURATION: follow-up only 2 months. Study was conducted in paediatric patients with chronic
maxillary sinusitis
Taccariello 1999 INTERVENTION - seawater spray versus alkaline saline irrigation
Ural 2009 DESIGN: intervention and follow-up only 10 days. A study of mucociliary clearance after using
hypertonic and isotonic nasal saline in patients with CRS, acute sinusitis, allergic rhinitis and normal
participants
Wendeler 1997 INTERVENTION: isotonic Emser (Epsom) salt (magnesium sulphate) solution versus tap water
CRS: chronic rhinosinusitis
Characteristics of ongoing studies [ordered by study ID]
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ISRCTN88204146
Trial name or title ’Steam inhalation and nasal irrigation for recurrent sinusitis’
Methods Pragmatic randomised controlled 2 x 2 factorial trial
Participants Patients (both males and females) aged 18 to 65 years with recurrent or chronic sinusitis
Interventions Daily nasal irrigation versus daily steam inhalation versus combined treatment group
Outcomes Primary outcome: severity of symptoms assessed by the Rhinosinusitis Disability Index (RSDI)
Secondary outcomes:
1. Quality of life assessed by the EQ-5D
2. Severity of sinus symptoms assessed by a Single Item Sinus Symptom Severity Assessment (SIA)
3. Severity of upper respiratory symptoms (coryza, sore throat, cough, earache, feeling unwell, fever)
4. Belief in the importance of antibiotics and seeing the doctor for sinusitis using validated Likert scales
5. Side effects of treatment (and also reported side effects for previous 3 months)
6. Compliance with irrigation/inhalation
7. Use of over the counter treatments (e.g. analgesics, decongestants)
8. Number of prescriptions for antibiotics for sinus-related symptoms
9. Number of prescriptions for antibiotics in total
10. Number of GP visits regarding sinus-related symptoms and for other respiratory symptoms
Starting date 2008
Contact information Prof Paul Little (p.little@soton.ac.uk)
Notes We contacted the study author. The trial is in the process of being written up for publication
NCT00335309
Trial name or title ’Effectiveness of maxillary sinus saline irrigation in conjunction with systemic antibiotic therapy versus sys-
temic antibiotic therapy alone in the management of chronic rhinosinusitis, a prospective randomized con-
trolled trial’
Methods Randomised, parallel assignment, open-label controlled trial
Participants Adults with chronic (over 3 months) maxillary and ethmoidal rhinosinusitis (verified by a CT scan)
Interventions Normal saline 0.9% versus no saline irrigation
Both arms have intravenous antibiotics of Augmentin 1 g 3 times a day for 4 days, and then per os (PO)
Augmentin 875 mg twice a day for another 10 days
Outcomes Primary outcome: CT scoring
Secondary outcomes: nasal endoscopy score, quality of life questionnaire
Starting date October 2005
Contact information Ohad Ronen, Carmel Medical Center
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NCT00335309 (Continued)
Notes We contacted the study author. The trial is in the process of being written up for publication
NCT02582099
Trial name or title ’The efficacy and complication of gentamicin nasal irrigation in chronic rhinosinusitis and recurrent sinusitis’
Methods Randomised, parallel assignment, double-blind controlled trial
Participants Children (7 to 18 years) with chronic rhinosinusitis and/or recurrent acute/subacute sinusitis
Interventions 1. Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each per nostril
2. Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each per nostril
Outcomes Primary outcome: frequency of sinusitis
Secondary outcome: none listed
Starting date 2015
Contact information Prof Nualanong Visitsunthorn (nualanongv@yahoo.com)
Notes Estimated date of completion is December 2016
TCTR20140323002
Trial name or title ’The effect of warm saline irrigation on mucociliary function in patients with chronic rhinosinusitis’
Methods Randomised, placebo-controlled, parallel assignment, single-blind controlled trial
Participants Adults with chronic rhinosinusitis
Interventions Warm saline nasal irrigation versus “placebo” (unclear comparator)
Outcomes Primary outcome: saccharine transit time
Secondary outcome: obstructive symptom score, comfort symptom score, peak nasal inspiratory flow, rhi-
nomanometry, acoustic rhinometry
Starting date 2014
Contact information Saran Ruxrungtham (saran.rux@gmail.com)
Notes We made attempts to contact the study author to find out further information but could not obtain this
CT: computed tomography
GP: general practitioner
PO: oral
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D A T A A N D A N A L Y S E S
Comparison 1. Nasal saline (hypertonic, 2%, large-volume) versus usual treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease-specific HRQL -
measured using RSDI (range 0
to 100)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 3 months follow-up 1 76 Mean Difference (IV, Fixed, 95% CI) 6.3 [0.89, 11.71]
1.2 6 months follow-up 1 76 Mean Difference (IV, Fixed, 95% CI) 13.5 [9.63, 17.37]
2 Disease severity - using
single-item score (range not
known)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 3 months follow-up 1 76 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.45, -0.35]
2.2 6 months follow-up 1 76 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.15, -1.04]
3 Generic HRQL - measured
using SF-12 (range 0 to 100)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 3 months follow-up 1 76 Mean Difference (IV, Fixed, 95% CI) 5.30 [-4.38, 14.98]
3.2 6 months follow-up 1 76 Mean Difference (IV, Fixed, 95% CI) 10.5 [0.66, 20.34]
4 Percentage of 2-week blocks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Sinus headache 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Frontal pain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Frontal pressure 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Nasal congestion 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Nasal discharge 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Intranasal steroids versus nasal saline (nebulised, small-volume)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity - overall score
(range not known)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 3 months follow-up (end
of treatment)
1 40 Mean Difference (IV, Fixed, 95% CI) -13.50 [-14.44, -12.
56]
1.2 6 months follow-up (3
months post end of treatment)
1 40 Mean Difference (IV, Fixed, 95% CI) -7.71 [-8.72, -6.70]
2 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Epistaxis 1 40 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 20.33]
2.2 Local irritation 1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
3 Endoscopy score - measured
using modified Lund-Mackay
(range unknown)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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3.1 3 months follow-up (end
of treatment)
1 40 Mean Difference (IV, Fixed, 95% CI) -14.57 [-15.15, -13.
99]
3.2 6 months follow-up (3
months post end of treatment)
1 40 Mean Difference (IV, Fixed, 95% CI) -7.37 [-8.22, -6.52]
Analysis 1.1. Comparison 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment, Outcome 1
Disease-specific HRQL - measured using RSDI (range 0 to 100).
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment
Outcome: 1 Disease-specific HRQL - measured using RSDI (range 0 to 100)
Study or subgroup Nasal saline Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months follow-up
Rabago 2002 52 14 (14.42221) 24 7.7 (9.308061) 100.0 % 6.30 [ 0.89, 11.71 ]
Subtotal (95% CI) 52 24 100.0 % 6.30 [ 0.89, 11.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.022)
2 6 months follow-up
Rabago 2002 52 14.4 (12.25887) 24 0.9 (4.898979) 100.0 % 13.50 [ 9.63, 17.37 ]
Subtotal (95% CI) 52 24 100.0 % 13.50 [ 9.63, 17.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.84 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.51, df = 1 (P = 0.03), I2 =78%
-100 -50 0 50 100
Favours usual care Favours nasal saline
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Analysis 1.2. Comparison 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment, Outcome 2
Disease severity - using single-item score (range not known).
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment
Outcome: 2 Disease severity - using single-item score (range not known)
Study or subgroup Nasal saline Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months follow-up
Rabago 2002 52 -1.2 (1.442221) 24 -0.3 (0.979796) 100.0 % -0.90 [ -1.45, -0.35 ]
Subtotal (95% CI) 52 24 100.0 % -0.90 [ -1.45, -0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
2 6 months follow-up
Rabago 2002 52 -1.6 (1.4422) 24 -0.01 (0.9798) 100.0 % -1.60 [ -2.15, -1.04 ]
Subtotal (95% CI) 52 24 100.0 % -1.60 [ -2.15, -1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.02, df = 1 (P = 0.08), I2 =67%
-2 -1 0 1 2
Favours nasal saline Favours usual care
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Analysis 1.3. Comparison 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment, Outcome 3
Generic HRQL - measured using SF-12 (range 0 to 100).
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment
Outcome: 3 Generic HRQL - measured using SF-12 (range 0 to 100)
Study or subgroup Nasal saline Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months follow-up
Rabago 2002 52 8.2 (20.9122) 24 2.9 (19.59592) 100.0 % 5.30 [ -4.38, 14.98 ]
Subtotal (95% CI) 52 24 100.0 % 5.30 [ -4.38, 14.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
2 6 months follow-up
Rabago 2002 52 12.7 (25.95997) 24 2.2 (17.14643) 100.0 % 10.50 [ 0.66, 20.34 ]
Subtotal (95% CI) 52 24 100.0 % 10.50 [ 0.66, 20.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
-100 -50 0 50 100
Favours usual care Favours nasal saline
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Analysis 1.4. Comparison 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment, Outcome 4
Percentage of 2-week blocks.
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 1 Nasal saline (hypertonic, 2%, large-volume) versus usual treatment
Outcome: 4 Percentage of 2-week blocks
Study or subgroup Nasal saline Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sinus headache
Rabago 2002 52 57 (0.360555) 24 76 (0.293939) -19.00 [ -19.15, -18.85 ]
2 Frontal pain
Rabago 2002 52 55 (0.360555) 24 82 (0.244949) -27.00 [ -27.14, -26.86 ]
3 Frontal pressure
Rabago 2002 52 53 (0.360555) 24 86 (0.244949) -33.00 [ -33.14, -32.86 ]
4 Nasal congestion
Rabago 2002 52 67 (0.288444) 24 83 (0.244949) -16.00 [ -16.13, -15.87 ]
5 Nasal discharge
Rabago 2002 52 65 (0.360555) 24 69 (0.342929) -4.00 [ -4.17, -3.83 ]
-100 -50 0 50 100
Favours nasal saline Favours usual care
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Analysis 2.1. Comparison 2 Intranasal steroids versus nasal saline (nebulised, small-volume), Outcome 1
Disease severity - overall score (range not known).
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 2 Intranasal steroids versus nasal saline (nebulised, small-volume)
Outcome: 1 Disease severity - overall score (range not known)
Study or subgroup INCS Saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months follow-up (end of treatment)
Cassandro 2015 20 6.6 (0.86) 20 20.1 (1.97) 100.0 % -13.50 [ -14.44, -12.56 ]
Subtotal (95% CI) 20 20 100.0 % -13.50 [ -14.44, -12.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 28.09 (P < 0.00001)
2 6 months follow-up (3 months post end of treatment)
Cassandro 2015 20 13.19 (1.71) 20 20.9 (1.55) 100.0 % -7.71 [ -8.72, -6.70 ]
Subtotal (95% CI) 20 20 100.0 % -7.71 [ -8.72, -6.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 14.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 67.40, df = 1 (P = 0.00), I2 =99%
-20 -10 0 10 20
Favours INCS Favours saline
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Analysis 2.2. Comparison 2 Intranasal steroids versus nasal saline (nebulised, small-volume), Outcome 2
Adverse events.
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 2 Intranasal steroids versus nasal saline (nebulised, small-volume)
Outcome: 2 Adverse events
Study or subgroup INCS Saline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Epistaxis
Cassandro 2015 2/20 1/20 100.0 % 2.00 [ 0.20, 20.33 ]
Subtotal (95% CI) 20 20 100.0 % 2.00 [ 0.20, 20.33 ]
Total events: 2 (INCS), 1 (Saline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Local irritation
Cassandro 2015 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (INCS), 0 (Saline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
0.01 0.1 1 10 100
Favours INCS Favours saline
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Analysis 2.3. Comparison 2 Intranasal steroids versus nasal saline (nebulised, small-volume), Outcome 3
Endoscopy score - measured using modified Lund-Mackay (range unknown).
Review: Saline irrigation for chronic rhinosinusitis
Comparison: 2 Intranasal steroids versus nasal saline (nebulised, small-volume)
Outcome: 3 Endoscopy score - measured using modified Lund-Mackay (range unknown)
Study or subgroup INCS Saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months follow-up (end of treatment)
Cassandro 2015 20 9.33 (0.91) 20 23.9 (0.97) 100.0 % -14.57 [ -15.15, -13.99 ]
Subtotal (95% CI) 20 20 100.0 % -14.57 [ -15.15, -13.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 48.99 (P < 0.00001)
2 6 months follow-up (3 months post end of treatment)
Cassandro 2015 20 16.58 (1.54) 20 23.95 (1.19) 100.0 % -7.37 [ -8.22, -6.52 ]
Subtotal (95% CI) 20 20 100.0 % -7.37 [ -8.22, -6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 186.59, df = 1 (P = 0.00), I2 =99%
-20 -10 0 10 20
Favours INCS Favours saline
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 MeSH descriptor: [Rhinitis] this term only
#3 MeSH descriptor: [Rhinitis, Atrophic] this term only
#4 MeSH descriptor: [Rhinitis, Vasomotor] this term only
#5 MeSH descriptor: [Paranasal Sinus Diseases] this term only
#6 MeSH descriptor: [Paranasal Sinuses] explode all trees
#7 rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis
#8 kartagener* near syndrome*
1 exp Sinusitis/
2 paranasal sinus diseases/ or rhinitis/ or rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*).ab,ti.
6 (inflamm* adj5 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 sinus*).ab,ti.
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(Continued)
#9 inflamm* near sinus*
#10 (maxilla* or frontal*) near sinus*
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Chronic Disease] explode all trees
#13 MeSH descriptor: [Recurrence] explode all trees
#14 chronic or persis* or recurrent*
#15 #12 or #13 or #14
#16 #11 and #15
#17 CRSsNP
#18 (sinusitis or rhinitis) near (chronic or persis* or recurrent*)
#19 #16 or #17 or #18
#20 MeSH descriptor: [Nasal Polyps] explode all trees
#21 MeSH descriptor: [Nose] explode all trees
#22 MeSH descriptor: [Nose Diseases] explode all trees
#23 #21 or #22
#24 MeSH descriptor: [Polyps] explode all trees
#25 #23 and #24
#26 (nose or nasal or rhino* or rhinitis or sinus* or sinonasal) near
(papilloma* or polyp*)
#27 rhinopolyp* or CRSwNP
#28 #19 or #20 or #25 or #26 or #27
#29 MeSH descriptor: [Solutions] this term only
#30 MeSH descriptor: [Hypertonic Solutions] this term only
#31 MeSH descriptor: [Saline Solution, Hypertonic] this term
only
#32 MeSH descriptor: [Hypotonic Solutions] explode all trees
#33 MeSH descriptor: [Isotonic Solutions] explode all trees
#34 MeSH descriptor: [Sodium Chloride] explode all trees
#35 MeSH descriptor: [Mineral Waters] explode all trees
#36 MeSH descriptor: [Seawater] explode all trees
#37 saline or “sodium chloride” or saltwater or hypertonic* or
hypotonic* or isotonic* or hypersaline or “sea water” or seawater
or ((salt* or thermal or mineral or sulfur* or bromic or iodic* or
bromide or iodine or bromine) and (water* or solution*))
#38 #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #
37
#39 MeSH descriptor: [Therapeutic Irrigation] this term only
#40 MeSH descriptor: [Nasal Lavage] explode all trees
#41 MeSH descriptor: [Administration, Inhalation] explode all
trees
#42 MeSH descriptor: [Administration, Intranasal] explode all
trees
#43 MeSH descriptor: [Nasal Sprays] explode all trees
#44 douch* or spray* or lavag* or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)
#45 intranasal or inhalation* or irrigator
#46 #39 or #40 or #41 or #42 or #43 or #44 or #45 or #45
#47 #38 and #46
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or recurrent*).ab,ti.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
ab,ti
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose Diseases/
19 exp Polyps/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).ab,ti
22 (rhinopolyp* or CRSwNP).ab,ti.
23 16 or 17 or 20 or 21 or 22
24 Solutions/
25 Hypertonic Solutions/
26 exp Sodium Chloride/
27 Saline Solution, Hypertonic/
28 exp Hypotonic Solutions/
29 exp Mineral Waters/
30 exp Isotonic Solutions/
31 exp Seawater/
32 (saline or “sodium chloride” or saltwater or hypertonic* or
hypotonic* or isotonic* or hypersaline or “sea water” or seawater
or ((salt* or thermal or mineral or sulfur* or bromic or iodic* or
bromide or iodine or bromine) and (water* or solution*))).ab,ti
33 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34 Therapeutic Irrigation/
35 exp Nasal Lavage/
36 exp administration, inhalation/ or exp administration, in-
tranasal/
37 exp Nasal Sprays/
38 Aerosols/
39 (douch* or spray* or lavag* or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)).ab,ti
40 (intranasal or inhalation* or irrigator).ab,ti.
41 34 or 35 or 36 or 37 or 38 or 39 or 40
42 ((nasal or intranasal or sinus or nose or sinonasal) adj3 (irriga-
tion* or rinsing or rinse* or wash* or lavage or douch* or hygiene)
).ab,ti
43 (sterimar or NeilMed or nasaline or navage or marimer or
physiomer or Emcur or “simply saline” or “nasal mist” or ayr or
salex or “otrovin saline” or ISCS or Prorhinel or SSBI).ab,ti
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#48 sterimar or NeilMed or nasaline or navage or marimer or
physiomer or Emcur or “simply saline” or “nasal mist” or ayr or
salex or “otrovin saline” or ISCS or Prorhinel or SSBI
#49 (nasal or intranasal or sinus or nose or sinonasal) near/3 (ir-
rigation* or rinsing or rinse* or wash* or lavage or douch* or hy-
giene)
#50MeSHdescriptor: [Mineral Waters] explode all trees and with
qualifier(s): [Therapeutic use - TU]
#51 #47 or #48 or #49 or #50
#52 #28 and #53
44 exp Mineral Waters/tu [Therapeutic Use]
45 41 or 42 or 43 or 44
46 23 and 45
Ovid EMBASE Trial registries (via CRS)
1 exp sinusitis/ or paranasal sinus disease/
2 atrophic rhinitis/ or chronic rhinitis/ or rhinosinusitis/ or vaso-
motor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).tw
5 (kartagener* adj3 syndrome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 sinus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recurrent*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
tw
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).tw
22 (rhinopolyp* or CRSwNP).tw.
23 16 or 17 or 20 or 21 or 22
24 solution and solubility/
25 hypertonic solution/
26 exp sodium chloride/
27 exp hypotonic solution/
28 exp mineral water/
29 exp isotonic solution/
30 exp sea water/
31 (saline or “sodium chloride” or saltwater or hypertonic* or
hypotonic* or isotonic* or hypersaline or “sea water” or seawater
ClinicalTrials.gov
Condition: rhinitis OR sinusitis OR rhinosinusitis OR (nose
AND polyp*) OR (nasal AND polyp*) OR CRSsNP OR CR-
SwNP OR CRS
ICTRP
Title: rhinitis OR sinusitis OR rhinosinusitis OR CRSsNP OR
CRSwNP OR CR
OR
All: (nose AND polyp*) OR (nasal AND polyp*)
NB These searches were run from 1 March 2015 to 11 August 2015,
when these terms were last searched to populate the Cochrane ENT
trials register in CRS
51Saline irrigation for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
or ((salt* or thermal or mineral or sulfur* or bromic or iodic* or
bromide or iodine or bromine) and (water* or solution*))).ab,ti
32 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
33 lavage/
34 exp nasal lavage/
35 exp inhalational drug administration/
36 exp intranasal drug administration/
37 exp nose spray/
38 aerosol/
39 (douch* or spray* or lavag* or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)).ab,ti
40 (intranasal or inhalation* or irrigator).ab,ti.
41 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40
42 ((nasal or intranasal or sinus or nose or sinonasal) adj3 (irriga-
tion* or rinsing or rinse* or wash* or lavage or douch* or hygiene)
).ab,ti
43 (sterimar or NeilMed or nasaline or navage or marimer or
physiomer or Emcur or “simply saline” or “nasal mist” or ayr or
salex or “otrovin saline” or ISCS or Prorhinel or SSBI).ab,ti
44 exp mineral water/ad, ih, th, tp [Drug Administration, Inhala-
tional Drug Administration, Therapy, Topical Drug Administra-
tion]
45 32 and 41
46 42 or 43 or 44 or 45
47 23 and 46
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
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Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
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• Previous courses of steroids: [add info on mean number of
courses if available]
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: [review specific]
Secondary outcomes:
• Health-related quality of life, generic
• [Other review specific, pre-specified adverse events]
• [Other review specific, pre-specified adverse events]
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
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Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
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(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
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Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/nose
bleed
INCS
Saline irrigation
Local irritation
(sore throat, oral
thrush, discom-
fort)
INCS
Saline irrigation
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
OCS
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
OCS
Antibiotics
Insomnia OCS
Os-
teoporosis (min-
imum 6months)
INCS
OCS
Discomfort Saline irrigation
Skin irritation Antibiotics
Anaphylaxis
or other serious
allergic reactions
such as Stevens-
Antibiotics
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Johnson
Comments:
C O N T R I B U T I O N S O F A U T H O R S
Lee Yee Chong: scoped, designed and wrote the protocol (Chong 2015). Abstract screening, full paper review, data extraction, data
analysis, drafting and writing the report.
Karen Head: reviewed and edited the protocol. Abstract screening, full paper review, data extraction, data analysis and editing the
report.
Claire Hopkins: clinical guidance at all stages of project scoping and protocol development. Clinical input into data analysis, reviewing
and editing the report.
Carl Philpott: clinical guidance at all stages of project scoping and protocol development. Clinical input into data analysis, reviewing
and editing the report.
Simon Glew: abstract screening, data extraction and clinical input into data analysis.
Glenis Scadding: abstract screening and clinical input into data analysis.
Anne GM Schilder: clinical guidance at all stages of project scoping and protocol development. Clinical input into data analysis,
reviewing and editing the report.
Martin Burton: clinical input into data analysis, reviewing and editing the report.
D E C L A R A T I O N S O F I N T E R E S T
Lee Yee Chong: none known.
Karen Head: none known.
Claire Hopkins: I have received financial support from several companies involved in producing instruments for sinus surgery: Acclarent,
Sinusys, Cryolife and Medtronic.
Carl Philpott: I have previously received consultancy fees from the companies Acclarent, Navigant, Aerin Medical and Entellus.
Simon Glew: none known.
Glenis Scadding: research grants from GSK and ALK. Honoraria for articles, lectures/chairing, advisory boards and consultancy:
Astra Zeneca, Brittania Pharmaceuticals, Capnia, Church & Dwight, Circassia, GSK, Groupo Uriach, Meda, Merck, MSD, Ono
Pharmaceuticals, Oxford Therapeutics, Sanofi-Aventis, Shionogi and UCB. Travel funding from ALK, Bayer, GSK and Meda.
Martin Burton: Professor Martin Burton is joint Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process for
this review.
Anne GM Schilder: Professor Anne Schilder is joint Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process
for this review. Her evidENT team at UCL is supported by her NIHR Research Professorship award with the remit to develop a UK
infrastructure and programme of clinical research in ENT, Hearing and Balance. Her institution has received a grant from GSK for a
study on the microbiology of acute tympanostomy tube otorrhoea.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
Funding to complete a suite of reviews on medical interventions for chronic rhinosinusitis in 2015/2016 (award reference 14/174/
03), in addition to infrastructure funding for Cochrane ENT
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As part of the discussions about the use of a total symptoms score we noted that many papers within the suite of reviews did not present
information for all four elements of the EPOS criteria for defining chronic rhinosinusitis (EPOS 2012). In particular, many studies
that only included patients with nasal polyps did not present information on facial pressure or pain. We made the decision that where
individual symptoms were recorded, they should be presented within the outcome of disease severity symptom score within the paper
as this information would be useful for the reader.
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